Adragos Pharma

Photo

The Evolution of the CDMO Industry

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.

Photo

CDMO Adragos to Buy Sanofi Site in Japan

Munich-based German CDMO Adragos Pharma said it has signed a definitive agreement with Sanofi’s Japanese subsidiary to acquire a pharmaceutical manufacturing site in Kawagoe, near Tokyo.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.